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1.  Tobacco smoking in 
South Africa 
There are an estimated 1.3 billion smokers worldwide 
and over 5 million deaths per year attributable to 
tobacco smoking.[1] Even though smoking rates are 
declining, there are an estimated 7 million smokers in South Africa 
(SA).[2] Tobacco smoking is undoubtedly the primary risk factor for 
chronic obstructive pulmonary disease (COPD), which is estimated 
to be the third highest cause of death globally by 2030. SA has a 
particularly high prevalence of smoking (20%).[3,4] SA also has one of 
the highest burdens of tuberculosis (TB) and HIV, which are both risk 
factors for COPD and exacerbate the effects of smoking. [5,6] Tobacco 
smoking increases the risk for TB, cancer, pneumonia, ischaemic heart 
disease and stroke, which are all leading causes of death globally.[1] The 
mortality among current smokers in SA is nearly double that of non- 
or ex-smokers.[7,8] Up to a third of all male deaths in SA adults over the 
age of 35 years have recently been attributed to tobacco use.[7,9] Passive 
smoking also increases the risk of cardiovascular disease in adults and 
respiratory disease, particularly among children. The cost of smoking-
related disease to the SA economy is estimated to be R1.2 billion.[10] 
The benefits of stopping smoking are almost immediate, with a 
lowering of blood pressure within minutes, and longer-term benefits 
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Tobacco smoking (i.e. cigarettes, rolled tobacco, pipes, etc.) is associated with significant health risks, reduced life expectancy and negative 
personal and societal economic impact. Smokers have an increased risk of cancer (i.e. lung, throat, bladder), chronic obstructive pulmonary 
disease (COPD), tuberculosis and cardiovascular disease (i.e. stroke, heart attack). Smoking affects unborn babies, children and others 
exposed to second hand smoke. Stopping or ‘quitting’ is not easy. Nicotine is highly addictive and smoking is frequently associated with 
social activities (e.g. drinking, eating) or psychological factors (e.g. work pressure, concerns about body weight, anxiety or depressed mood). 
The benefits of quitting, however, are almost immediate, with a rapid lowering of blood pressure and heart rate, improved taste and smell, 
and a longer-term reduction in risk of cancer, heart attack and COPD. Successful quitting requires attention to both the factors surrounding 
why an individual smokes (e.g. stress, depression, habit, etc.) and the symptoms associated with nicotine withdrawal. Many smokers are 
not ready or willing to quit and require frequent motivational input outlining the benefits that would accrue. In addition to an evaluation 
of nicotine dependence, co-existent medical or psychiatric conditions and barriers to quitting should be identified. A tailored approach 
encompassing psychological and social support, in addition to appropriate medication to reduce nicotine withdrawal, is likely to provide 
the best chance of success. Relapse is not uncommon and reasons for failure should be addressed in a positive manner and further attempts 
initiated when the individual is ready.
Key steps in smoking cessation include: (i) identifying all smokers, alerting them to the harms of smoking and benefits of quitting; 
(ii) assessing readiness to initiate an attempt to quit; (iii) assessing the physical and psychological dependence to nicotine and smoking; 
(iv) determining the best combination of counselling/support and pharmacological therapy; (v) setting a quit date and provide suitable 
resources and support; (vi) frequent follow-up as often as possible via text/telephone or in person; (vii) monitoring for side-effects, relapse 
and on-going cessation; and (viii) if relapse occurs, providing the necessary support and encourage a further attempt when appropriate.
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such as improved lung function and reduced risk for lung cancer, 
stroke and heart disease. Smoking cessation is a critical component of 
the effective management of COPD.[11] Savings of disposable income, 
achieved by quitting smoking, would also be available for basic 
necessities, particularly for those living in poverty. 
Many smokers have no desire to quit and will require repeated 
engagement by health practitioners to affect behaviour change. 
Interviewing techniques have changed from the more traditional 
approach, typified by scolding or lecturing, to one that involves 
support, encouragement and the provision of information.[12] For 
those who wish to stop there are many options available such as ‘cold 
turkey’, cognitive behavioural therapy, acupuncture, hypnosis, internet 
and cellular phone-based support programmes, and medication. 
This guideline assesses published evidence and reviews international 
guidelines, applying them to the specific needs and circumstances in 
SA in developing a clinical practice guideline for SA clinicians. 
Published international guidelines from the US Centers for Disease 
Control, the American College of Chest Physicians (ACCP), the UK 
National Institute for Clinical Excellence (NICE) and the Cochrane 
Collaboration Database of Systematic Reviews for all topics relating to 
tobacco smoking were reviewed. In addition, PubMed was searched 
for newer studies on specific topics such as e-cigarettes, smoking in 
pregnancy, and smoking in persons infected with HIV or TB. Smoking 
in this guideline refers to all forms of smoking tobacco products such as 
cigarettes, cigars and rolled tobacco. Smoking cessation – also referred 
to as quitting, is the process of stopping smoking. Where available, 
evidence grading is provided with the grading source.
2.  Tobacco smoking cessation strategies
Smoking cessation can be broadly divided into two phases: (i)  the 
identification of smokers and assisting them to quit; and (ii) initiating 
and sustaining the quit attempt (Fig. 1). The strength of evidence for 
each intervention varies. For each stage and intervention, key points 
and strength of supporting data are presented and expert opinion was 
relied on where data was lacking. 
2.1 Identifying smokers and initiating quit attempts 
• The strategy of identifying smokers during routine consultations 
with healthcare practitioners increases quit attempts (Grade A[13]).
• Brief smoking cessation interventions should be implemented, 
regardless of the availability of, and access to, specialised services 
(Grade A[13]).
‘If you don’t think about it, you won’t do it’. Using stickers, tags or 
reminders in folders for the nurses or doctors increases the likelihood 
of discussions with patients around smoking, counselling and referral 
for cessation advice. The inclusion of smoking as one of the vital signs 
identifies 80% or more of smokers attending primary care facilities.[14] 
2.2  Clinical interventions to initiate and sustain smoking 
cessation 
• Repeated encouragement and assistance provided by more than 
one physician/healthcare worker, through a range of supportive 
options, increase the likelihood of abstinence (Grade A[13]).
Interventions as brief as 3 min can significantly increase quit rates, 
but intensive interventions are more effective (more comprehensive 
treatments being those that occur over multiple visits, for a longer 
period of time and/or are provided by more than one clinician). [14] 
The goal should be for every tobacco user to be identified and offered 
at least a brief intervention at every clinical consultation. A commonly 
recommended approach is the 5As model, which is an effective, 
structured approach to providing brief interventions (3 - 10 min) in 
the primary care setting. The 5 steps are: (i) asking about smoking; 
(ii)  alerting the patient to the benefits of quitting; (iii) assessing 
readiness to make a quit attempt; (iv) assisting those willing to 
quit; and (v) arranging for follow-up contact and referral to further 
resources, such as quitlines. Problem solving, skills training and 
psychosocial support during treatment are all effective elements of 
counselling. They can be used as part of brief interventions, but also 
form the foundation of more intensive interventions.[14]
2.3 Motivational interviewing approach
Many patients lack the motivation to quit or express a lack of 
readiness to quit. This may be because they lack information, 
have concerns about quitting, face significant social/environmental 
barriers or lack confidence in their ability to quit. Such patients 
may benefit from counselling methods derived from motivational 
interviewing (MI).[12] 
In this approach, the clinician encourages the smoker to explore 
their feelings of ambivalence about smoking/quitting by discussing, 
for example, the pros and cons of smoking from their perspective, 
and by exploring how personally important cessation may be and 
how confident they feel about it. In this process, the provider 
supports and strengthens any intentions to change, which come 
from the patients themselves. The idea is to elicit self-motivational 
statements, rather than tell the patient what they should do and how 
they should do it. MI posits that a good collaborative relationship, in 
which a client is viewed as the expert on his/her own life, serves to 
minimise resistance to change and thereby enhances motivation.[15] 
This varies significantly from the traditional, advice-giving approach, 
which casts the provider in a dominant, directing role and the 
patient merely as a passive recipient of their expert knowledge. Meta-
analyses have shown that MI can significantly improve smoking 
cessation rates over brief advice.[16]
2.4 The individual who is not ready to quit
• Encourage the individual to think about quitting, identify the 
reasons for smoking and the barriers to quitting and provide an 
opportunity for follow-up.
For individuals who are not ready or willing to quit, on-going 
encouragement and offers of support are necessary. The practitioner 
can provide information about the risks of smoking and the benefits 
of quitting and encourage the patient to return for further discussions 
if and when they are ready to quit. Assisting the patient to identify 
the perceived benefits that they gain from smoking (i.e. stress 
reduction, weight control), their perceived barriers to quitting (i.e. 
social pressure, withdrawal symptoms) and the benefits of quitting 
(i.e. health improvement, cost savings) can lay the foundation to 
behavioural change at a later date and enhance the possibility of a 
quit attempt. 
2.5 Assisting the motivated patient to quit
• Counselling plus medication to treat nicotine withdrawal is more 
effective than either intervention alone (Grade A[13]).
• Multiple options are available and can be tailored to suit the 
individual patient and circumstance.
• Smokers who are motivated, have supportive networks and are 
ready to change, have higher success rates. 
• Smokers who are highly nicotine dependent, have social stressors 
and psychiatric comorbidities, are less likely to be successful.
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1. Do you smoke?
2. Do you know the risks?
3. Have you thought of quitting?
1. Do you know the benets of quitting?
2. Do you know that we can help you?
1. Are you ready to quit?
Ask
Alert
Assess
Assist/Arrange
No
Maybe Yes
Quitlines and useful websites
· National Council Against Smoking 
  quitline: 011 720 3145
· CANSA Call Centre: 0800 22 66 22
  website: http://www.ekickbutt.org.za
· Patient resources: http:/www.ichange4health.co.za
Arrange for cessation 
intervention
Give motivational pamphlet and 
encourage follow-up
Specic nicotine dependence review
Fagerström/CO levels
Current smoking and history of quit attempts
Social stressors/household smokers Motivated
High dependence
Probably will need added 
pharmacological support
Assess medical/psychiatric history
Evaluate capacity to purchase 
medicine
Review availability of medication
Motivated
Low dependence
Could manage with counselling/ 
support alone or NRT
Support group
Text/internet/smartphone-based 
support
Set quit date
Arrange appropriate support and 
medication if needed
Follow-up
· Assess withdrawal syptoms and 
drug side-eects
· Evaluate mood and psychosocial 
stressors
· Identity potential for relapse
Medication options
· Nicotine replacement therapy
  patch/gum/spray
· Varenicline
· Bupropion
Have you 
already 
attempted 
to quit 
smoking?
How many 
times do 
you smoke 
per day?
How soon after 
waking in the 
morning do 
you smoke your 
rst cigarette?
Level of 
dependence
Yes
Yes
Yes
No
>30
20 - 30
10 - 20
<10
>5 min
5 - 30 min
30 - 60 min
>60 min
Very high
High
Medium
Low
Fig. 1. Smoking cessation approach in clinical practice. All smokers should be identified and their readiness to quit evaluated. If resistance to quitting exists, 
information and suitable follow-up should be provided (top). If an individual is ready to make a quit attempt, evaluation of nicotine dependence, co-morbid disease 
and psychosocial factors should guide the clinician in the choice of effective interventions (bottom). CO = carbon monoxide; NRT = nicotine replacement therapy.
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3.  Pharmacological intervention (drug 
treatment to aid smoking cessation)
Several pharmacological strategies are available to assist in smoking 
cessation – predominantly to address acute nicotine withdrawal. 
These may be simply classified as nicotine replacement therapies 
(NRTs) or drugs that reduce addiction. Although both classes 
of drug are an aid to smoking cessation, they have little or 
no effect on the underlying addiction and do not address the 
psychosocial factors that cause a person to smoke. Most studies 
of pharmacological interventions have been conducted in subjects 
who smoke >10  cigarettes/day and frequently >20  cigarettes/day. 
There is little evidence to guide the use of pharmacological therapy 
in subjects who smoke only 3 - 5  cigarettes/day or in those with 
very low nicotine dependence. Table 1 outlines the comparative 
performance of the various drugs available to assist in smoking 
cessation. 
3.1 NRT
• NRT is effective and should be encouraged (Grade A[13]).
• A controller (patch) and reliever (gum, spray) approach is the most 
effective way to use NRT (Grade A[13]).
NRT has been the mainstay for addressing nicotine withdrawal. It is 
particularly effective when employing dual NRT – one as a ‘controller’ 
and one as a ‘reliever’ (odds ratio (OR) 3.6 (95% confidence interval 
(CI) 2.5 - 5.2) for success, and abstinence rates 36.5% (95% CI 28.6 
- 45.3) at the end of therapy).[14] This approach, which is advocated 
by the ACCP, is more effective than using a single form of NRT 
(relative risk (RR) 1.34; 95% CI 1.18 - 1.51).[17] Titration of the NRT 
(via patch strength) to the level of symptom severity based on the 
Fagerström scale (Table 2), or of cotinine level is recommended to 
ensure that adequate control of withdrawal symptoms is achieved. 
If ‘breakthrough’ symptoms occur the ‘reliever’ NRT should be used 
(gum, spray, etc.) The use of nicotine spray may be preferred to gum 
in some individuals.[18] Combinations of NRT with bupropion are 
more effective than NRT alone (OR 2.57; 95% CI 1.05 - 6.32),[19] but 
based on the theory of their mechanism of action, there should be no 
value in using both NRT and varenicline together. Despite this, there 
are anecdotal reports of additional benefit, and this has recently been 
tested in the VARNIC study, the results of which are expected during 
2014. Note: at the time of writing these practice guidelines, nicotine 
patches were not available in SA.
3.2 Antidepressants
• Bupropion is an effective drug for smoking cessation particularly 
in combination with NRT (Grade A[13]).
• Nortriptyline is a moderately effective drug for smoking cessation 
(Grade A[13]).
• The use of bupropion or nortriptyline must be under medical 
supervision due to potential side-effects and interactions.
Bupropion (Zyban) used at doses of 150 mg twice daily for 7 - 12 weeks 
is effective (RR 1.69; 95% CI 1.53 - 1.85).[20] Additionally, bupropion 
appears to reduce long-term relapse and the weight gain associated 
with quitting.[21] Its most frequent side-effects are insomnia, dry mouth 
and nausea.[20] Bupropion may also reduce the seizure threshold and 
a seizure risk of 1/1  000 has been reported.[22] There is no evidence 
that selective serotonin re-uptake inhibitors (SSRIs) are effective for 
smoking cessation.[20]
Nortriptyline (not registered in SA) is generally considered a second-
line therapy for those who have failed NRT and bupropion/varenicline. [23] 
Nortriptyline is a metabolite of amitriptyline, which is available in 
SA. There are, however, no published data on smoking cessation 
using amitriptyline. Given the increased associated risk of suicide in 
smokers,[24,25] the serious complications of amitriptyline overdose and 
its unknown efficacy as a smoking cessation aid, the drug cannot be 
recommended for smoking cessation until further data are available.
3.3 Nicotine receptors agonists
• Varenicline is an effective smoking cessation therapy (Grade A[13]).
• Although not confirmed in large studies and meta-analyses, there 
is concern about incidents of suicide or suicidal behaviour. 
• It is strongly advised that all patients who are prescribed these 
drugs are closely monitored for behavioural change and/or 
neuropsychiatric symptoms.
Two nicotine receptor partial agonists have been marketed: 
varenicline (Champix – registered in SA) and cytisine (Tabex – 
not registered in SA). By acting as partial agonists, they stimulate 
dopamine release and reduce nicotine withdrawal symptoms. [26-28] 
In controlled trials and meta-analyses, varenicline has been shown 
to be the most effective single drug for smoking cessation (RR 3.1; 
95% CI 2.5 - 3.8)[29,30] whereas cytisine, although effective, appears to 
result in only a modest increase in quit rates.[29,31] The most common 
side-effects reported with varenicline include abnormal dreams, 
Table 1. Comparisons of abstinence rates achieved with different pharmacological interventions to support smoking cessation*
Medication Arm, n OR (95%CI) Estimated abstinence rate (95%CI)
Placebo 80 1 13.8
NRT
Nicotine gum 15 1.5 (1.2 - 1.7) 19 (16.5 - 21.9)
Nicotine patch 32 1.9 (1.7 - 2.2) 23.4 (21.3 - 25.8)
Nicotine spray 4 2.3 (1.7 - 3) 26.7 (21.5 - 32.7)
Antidepressants/centrally acting agents
Bupropion SR 26 2 (1.8 - 2.2) 24.2 (22.2 - 26.4)
Nortriptyline 5 1.8 (1.3 - 2.6) 22.5 (16.8 - 29.4)
Clonidine 3 2.1 (1.2 - 3.7) 25 (15.7 - 37.3)
Nicotine receptor agonist
Varenicline (2 mg/day) 5 3.1 (2.5 - 3.8) 33.2 (28.9 - 37.8)
OR = odds ratio; CI = confidence interval; NRT = nicotine replacement therapy; SR = slow release.
*Data from Fiore et al.,[13] comparisons are with placebo treatment.
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nausea and headache. [32,33] While smokers 
as a group are at higher risk of suicide 
than non-smokers,[24,25] there are concerns 
about the neuropsychiatric side-effects of 
varenicline. While the US Food and Drug 
Administration (FDA) mandated a ‘black 
box’ warning in 2008, meta-analyses have 
not confirmed this risk.[29,34] Recent studies 
have also reported that varenicline appears 
to be safe in patients with schizophrenia[35] 
and in patients with cardiac disease.[29,36-38] 
Nevertheless, it should be used with caution 
and under supervision. Champix is a 
schedule 5 drug in SA and patients should 
be monitored regularly with particular 
attention to changes in their emotional state, 
unusual behaviour and suicidal ideation. 
3.4 Electronic cigarettes 
• There is no evidence that electronic 
cigarettes (e-cigarettes) are effective aids 
to smoking cessation, although they may 
reduce the number of cigarettes smoked.
E-cigarettes are battery-powered devices, 
similar in appearance to conventional 
cigarettes that vaporise nicotine. A large 
variety of products are on offer. They are 
available in different flavours and may be 
used in an attempt to reduce the symptoms 
of nicotine withdrawal while allowing the 
smoker to participate in the ‘ritual’ of smoking. 
E-cigarettes are available over the counter and 
there is currently little legislative control on 
their use, availability and marketing. Recently 
however, both the FDA and the South African 
Medicines Control Council have begun to 
consider regulation of these products.[39]
The role of e-cigarettes in smoking cessation 
algorithms remains unclear. As they are likely 
to be less hazardous than tobacco smoking,[40] 
they may, in future, have a role in smoking 
cessation, either to reduce nicotine intake or 
as a bridge to smoking cessation. In a small 
pilot study, they appeared to decrease cigarette 
consumption,[41] and they may be especially 
useful in reducing consumption in chronic 
psychiatric (schizophrenic) patients.[42] Side-
effects include mouth and throat irritation, 
dry cough, nausea and headache, although 
these appear to decrease over time. Concerns 
have been raised about the long-term safety 
of e-cigarettes, particularly with regard to 
the flavouring used.[43] Additionally, although 
e-cigarettes do not produce classic smoke, 
they have been found to produce short-term 
adverse physiological effects on the airways. [44] 
Currently, given the lack of data on efficacy 
and limited long-term safety data, they are not 
recommended as part of smoking-cessation 
strategies. 
3.5 Nicotine vaccine
• The theory behind nicotine vaccines is that 
they induce antibodies that bind to nicotine, 
reducing its availability to central receptors. 
• Nicotine vaccines are still in development 
and their efficacy has not been confirmed.[45]
3.6 Complementary medicine 
Several forms of complementary medical 
approaches are in common use and are widely 
advertised as aids to smoking cessation. 
These include hypnotherapy, acupuncture, 
acupressure and electro-stimulation. However, 
none of these methods are supported by 
convincing efficacy data when subjected to 
review using Cochrane Library methods. 
Although positive results have been reported 
in individual studies, there is a lack of data 
from large, randomised, controlled studies. 
When performed by experienced and qualified 
individuals, they are likely to be safe and 
may benefit some. However, they are not 
recommended as effective strategies.
3.6.1 Hypnotherapy
• There is no evidence to support hypno-
therapy as an effective aid to smoking 
cessation.
Hypnotherapy is a widely promoted aid to 
smoking cessation and multiple approaches, 
techniques and success rates have been 
reported. Two recently published meta-
analyses, in which different study selection 
criteria were employed, concluded that 
hypnotherapy was not effective, as insufficient 
quality data existed comparing hypnotherapy 
with other methods for smoking cessation. 
Estimates in the two separate meta-analyses for 
success of hypnotherapy in achieving smoking 
cessation were: OR 4.55 (95% CI 0.98 - 21.01) [46] 
and RR 1.49 (95% CI 0.86 - 2.5)[47]
Table. 2. Fagerström test for nicotine dependence[85]
Question Score
1. How soon after you wake up do you smoke your first cigarette?
Within 5 min 3
6 - 30 min 2
31 - 60 min 1
After 60 min 0
2.  Do you find it difficult to refrain from smoking in places where it is 
forbidden?
Yes 1
No 0
3. Which cigarette would you hate most to give up?
The first in the morning 1
Any other 0
4. How many cigarettes per day do you smoke?
≤10 0
11 - 20 1
21 - 30 2
≥31 3
5.  Do you smoke more frequently during the first hours after waking than 
during the rest of the day?
Yes 1
No 0
6. Do you smoke even if you are so ill that you are in bed most of the day?
Yes 1
No 0
TOTAL SCORE
Interpretation of total score[86]
0 - 3 Mild dependence
4 - 6 Moderate dependence
7 - 10 Severe dependence
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3.6.2 Acupuncture 
•  ‘There is no consistent, evidence that either acupuncture or 
acupressure are effective in smoking cessation’.[48]
Several studies and meta-analyses have evaluated the effects of 
acupuncture on smoking cessation in a controlled, randomised 
manner.[48-50] Differing methods used in these studies (e.g. the nature of 
control procedures and the selection of control groups) do not provide 
sufficient consistency for a bias-free analysis. The most recent and 
comprehensive Cochrane review concluded that acupuncture is less 
effective than NRT (RR 1.05; 95% CI 0.82 - 1.35).[48]
4.  Smoking cessation in specific 
situations
4.1 Pregnancy 
• Smoking poses significant risks to mother and fetus. 
• Brief counselling by a healthcare provider as part of routine 
antenatal care is effective and well received by pregnant women. 
• There is, as yet, insufficient, high-quality evidence to determine 
whether the use of pharmacotherapy (i.e. NRT, bupropion or 
varenicline) is effective and safe during pregnancy.
The risks to mother and child from smoking during pregnancy, and 
in the post-natal period are well established. Maternal smoking is 
associated with obstetric risks (miscarriage and premature rupture 
of membranes, placental abruption, intra-uterine growth retardation 
and stillbirth).[51] Maternal exposure to second-hand smoke in 
pregnancy can also increase the risk of low-birthweight children. [52] 
Although quitting early in pregnancy will produce the greatest 
benefits, stopping at any stage during pregnancy yields benefits to 
the fetus and mother, and the child in the postnatal period.[53] Passive 
smoking increases the risk for asthma, middle ear and recurrent chest 
infections in children. [54] Counselling should be offered at the first 
antenatal visit and if possible, smokers in the household or workplace 
should be identified. A smoking cessation intervention involving 
brief counselling by lay counsellors, supported by midwives and by 
educational materials specifically tailored to pregnancy, was shown 
to be effective in increasing cotinine-validated quit rates among 
disadvantaged women attending public sector antenatal care clinics 
in SA.[55] On the basis of the substantial evidence of benefit from NRT 
in the general population and the limited evidence available among 
pregnant women,[53,56,57] some guidelines recommend the use of NRT 
in pregnancy under medical supervision, but only when behavioural 
therapy has failed and in heavily dependent smokers who remain 
motivated to quit.[58] 
4.2 Adolescents/paediatrics 
• Treatment strategies relying on behavioural change are effective.
• No smoking cessation medication is licensed for use in children 
aged less than 18 years.
• Paediatricians and healthcare workers providing care to children must 
address smoking by parents and advise on smoking-cessation strategies.
Tobacco smoking in adolescents frequently leads to long-term 
nicotine addiction and the consequent adverse health-effects. In 
SA in 2008, 21% of learners (grade 8 - 10) were found to be current 
smokers, with 6.8% having initiated smoking before the age of 10 
years.[59] The smoking of hookah pipes (‘hubbly-bubbly’) should be 
addressed among adolescents who frequently believe it to be tobacco-
free and, hence, safe. Preventing adolescents from starting to smoke is 
vital to reduce the numbers of adults who smoke. 
Nearly half of adolescent smokers in SA attempt to quit each year 
but factors such as stress, depression, peer pressure and weight gain 
impact on their success.[59-62] Behavioural change can be encouraged 
by focussing on the health benefits and improved school and sport 
performance, and by recognising the effects of cultural differences 
and the social pressures that exist with regard to smoking.[60-62] A 
variety of methods (ranging from one-on-one sessions to group 
therapy, telephonic helplines and web-based programmes) have been 
tried and, if tailored to individual needs, may double success rates. 
There are insufficient studies comparing these models in order to 
recommend one particular strategy in adolescents.[13,63] It is imperative 
to speak to the adolescent alone (without the caregiver present) and 
to maintain confidentiality when encouraging behavioural change. 
SA data show that adolescents who have been exposed to smokers 
are more likely to smoke than those who have not (74.5% v. 44%, 
respectively).[59] Counselling of parents on the harmful effects of 
smoking and on interventions to aid quitting may reduce secondary 
smoke exposure in children.[13] Parental smoking cessation is also 
associated with higher quit rates among adolescents.[62,64]
No smoking-cessation medications are FDA-approved in children 
or adolescents (under 18 years). The UK NICE guidelines, however, 
support the use of NRT if required, along with behavioural interventions 
in teenagers over 12 years of age.[58] If a decision is made to use NRT in 
a teenager, it should be used in conjunction with behavioural therapy 
and should be individualised. Although safety studies have been 
conducted with bupropion and varenicline in adolescents, both are 
only approved for adults in SA.[33]
4.3 Tuberculosis
• Smokers have approximately double the risk of developing TB and 
of dying from TB than non-smokers.
• Smoking cessation for people with active TB is a feasible and 
effective intervention.
There is substantial epidemiological evidence that smokers have 
a higher risk of developing TB (both latent and active) and dying 
from TB.[65-67] In SA, with the added risk of HIV, the importance of 
smoking cessation to reduce the risk of TB, HIV-related diseases 
and COPD is unquestionable.[6,68] There are some data to show that 
integrating smoking cessation efforts (support plus NRT) with TB 
treatment is feasible,[69] improves quit rates (77% v. 8.7%, respectively) 
and completion of TB treatment (97.5% v. 84.8%, respectively).[70] It 
is unclear, however, whether stopping smoking during TB therapy 
will reduce the excess mortality associated with smoking and TB,[71] 
nor are there any efficacy data available on whether using bupropion 
or varenicline with concomitant anti-TB therapy may be of benefit. 
Smoking cessation should, however, be encouraged in all TB patients 
and appropriate support provided.
4.4 HIV/antiretroviral therapy
• Smoking cessation is an important and effective intervention in 
individuals living with HIV.
• Drug-drug interactions may occur with bupropion.
The risks of smoking in HIV-infected individuals are well described 
and include inter alia pneumonia, TB and lung cancer.[72] There are 
several small trials on smoking cessation in the context of HIV that 
have concluded that it is an important and effective intervention. [72-74] 
Smoking and nicotine are known to induce hepatic enzymes,[75,76] but 
not those metabolising common antiretrovirals (ARVs). Enzyme 
inhibition/induction by ARVs such as lopinavir-ritonavir may 
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increase or reduce serum concentrations of bupropion and should be 
used with caution.[74] Varenicline is not metabolised by the liver, thus 
drug-drug interactions should not occur, but common side-effects 
such as nausea may interfere with ARV compliance.[73] 
4.5 Mental illness
• Smoking is common in individuals with mental illness.
• Adequate management of the underlying psychiatric illness is key 
to successful smoking cessation.
Anxiety disorders, depression, and schizophrenia are strongly 
associated with tobacco smoking.[35,77,78] There is evidence to suggest that 
psychiatric disorders may lead to self-medication with nicotine and 
that smoking may predispose individuals to mental illness.[78,79] Smoking 
cessation is important even in those with complex psychiatric disorders. 
Where necessary, consultation with an experienced psychiatrist may be 
beneficial in choosing the best options for management of the mental 
illness and drugs for smoking cessation if required. A recent Cochrane 
review concluded that bupropion and varenicline appear to be safe and 
effective in schizophrenia, but NRT and psychological interventions 
show no benefit.[35] In patients with current depression, management of 
the depression should be addressed first, as there is limited success of 
smoking cessation interventions (even bupropion).[77] 
4.6 In-hospital cessation
• In-hospital cessation counselling with post-discharge follow-up is 
an effective intervention to assist in smoking cessation.
• The addition of NRT substantially improves quit rates, but insufficient 
data exist as to the additional benefits of bupropion or varenicline. 
As smoking is banned in most public places and particularly in 
hospitals, acute admissions in which smoking cessation is imposed are 
convenient opportunities to promote smoking cessation. Many trials 
have demonstrated that appropriate in-hospital counselling and post-
discharge follow-up are effective.[80] The additional use of NRT appears 
to be highly effective (54% increase in cessation rates).[80] There are 
insufficient data concerning the use of bupropion or varenicline during 
hospitalisation. Acute pre-operative cessation has mixed reports of long-
term success, although lower complication rates (in relation to wound 
healing and lung function) occur in those who quit at least 6 - 8 weeks 
prior to surgery.[81-84]
5. Relapse
Relapse is common; frequently, because the underlying psychosocial 
factors or nicotine addiction have not been adequately addressed. 
Relapses can be viewed as an opportunity to learn how to approach 
a subsequent quit attempt, rather than as outright failure. Many 
attempts may be required before long-term success is achieved. If 
relapse does occur, appropriate support should be provided and the 
reasons for relapse reviewed before another quit attempt. 
6.  Implementation and further research
Smoking cessation at the primary level will require adequate training 
of staff to provide the necessary counselling to motivate patients to 
attempt to quit. Lay counsellors providing HIV adherence support 
could be trained to offer smoking cessation counselling and support. 
The prescription of medication to support quit attempts may need to 
be restricted to clinicians/clinics who are able to fully assess nicotine 
dependence and monitor side-effects of the medication. Research 
into the optimal use of medications in HIV/TB patients as well as the 
possible use of amitriptyline is needed. 
7. Summary and recommendations
Nicotine addiction and psychosocial stressors make smoking cessation 
difficult, even in those who are motivated to quit. Motivating those with 
no apparent interest in quitting nor confidence to quit, requires support 
and encouragement from healthcare practitioners at every contact and 
should involve the entire health team. Although time is limited in clinical 
practice, brief motivational counselling with appropriate referral of the 
individual who is motivated to quit, is effective. 
These practice guidelines serve as an aid to the clinician in deciding 
on the best strategies to use for smoking cessation. Even the best 
programmes internationally have only modest success rates, with 
frequent relapses if the underlying reasons predisposing to smoking or 
the barriers to cessation have not been addressed. Informing the smoker 
about the immediate and long-term benefits of quitting, anticipating the 
difficulties that could be expected and problem solving with the patient, 
as well as prescribing appropriate medication where needed, all increase 
the possibility of success. If such interventions are widely applied to a 
large proportion of smokers, they have the potential to achieve important 
reductions in disease and associated excess healthcare costs. 
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